A potentially scalable method for the harvesting of hMSCs from microcarriers

Mixing theory for culture and harvest in bioreactors of human mesenchymal stem cells on microcarriers

“…In all cases after both culture and harvesting, in order to identify whether there had been any change in the hMSCs as a result of their treatment, they were analysed: 1) according to the International Society of Cell Therapy (ISCT) panel of markers to ascertain their immunophenotypic expression; 2) by tissue-culture adherence and morphology; and 3) for their multilineage differentiation potential [7,8]. All were appropriate showing that the cells maintained the desired quality attributes for therapeutic usage.…”

Bioprocess engineering strategies for autologous human MSC-based therapies: one size does not fit all

“…More particularly, the new generation of downstream processes should be able to address the increasing volumes and batches of cells produced at the upstream stages, but also possess flexibility in operation for supporting numerous autologous expansion processes. For instance, MSC harvest from microcarriers in suspension bioreactors was recently investigated providing a scalable methodology [61], while in a follow up study the authors linked this process to the subsequent cryopreservation step [36,61]. Dynamic harvest of single cells from fixed bed bioreactors was also recently described for the recovery of periost derived progenitor cells which retained their bone froming potential in vivo [62].…”

Advances in cell culture: anchorage dependence

“…B 370: 20140040 proteolytic agent should be as short as possible. Based on this observation, Nienow et al [141] evaluated a novel two-step protocol for trypsinization of hMSCs comprised of the addition of and incubation with trypsin-ETDA for 7 min at a fivefold increased agitation rate (30 ! 150 r.p.m., followed by 200 r.p.m.…”